Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
901 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01853826 | An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s) | completed | Phase 3 | 481 | Boehringer IngelheimINDUSTRY | 11 | Apr 11, 2025 | clinicaltrials |
| NCT03643276 | Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017 | recruiting | Phase 3 | 5,000 | Martin SchrappeOTHER | 8 | Apr 6, 2025 |
| clinicaltrials |
| NCT05079230 | Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia(ENHANCE-3) | terminated | Phase 3 | 378 | Gilead SciencesINDUSTRY | 20 | Apr 4, 2025 | clinicaltrials |
| NCT04164901 | Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO) | active not recruiting | Phase 3 | 331 | Institut de Recherches Internationales ServierOTHER | 11 | Apr 3, 2025 | clinicaltrials |
| NCT03635983 | A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma | completed | Phase 3 | 783 | Bristol-Myers SquibbINDUSTRY | 27 | Apr 1, 2025 | clinicaltrials |
| NCT04199689 | Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049) | active not recruiting | Phase 3 | 6,033 | Merck Sharp & Dohme LLCINDUSTRY | 16 | Mar 25, 2025 | clinicaltrials |
| NCT00490139 | ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D(ALTTO) | completed | Phase 3 | 8,381 | Novartis PharmaceuticalsINDUSTRY | 44 | Mar 21, 2025 | clinicaltrials |
| NCT00667251 | Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer | completed | Phase 3 | 652 | Novartis PharmaceuticalsINDUSTRY | 21 | Mar 21, 2025 | clinicaltrials |
| NCT02492711 | Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer(SOPHIA) | completed | Phase 3 | 624 | MacroGenicsINDUSTRY | 18 | Mar 17, 2025 | clinicaltrials |
| NCT01160211 | A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer | completed | Phase 3 | 369 | Novartis PharmaceuticalsINDUSTRY | 29 | Mar 7, 2025 | clinicaltrials |
| NCT01958021 | Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer(MONALEESA-2) | completed | Phase 3 | 668 | Novartis PharmaceuticalsINDUSTRY | 29 | Mar 7, 2025 | clinicaltrials |
| NCT01924819 | Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma(TOPGEAR) | active not recruiting | Phase 2 / Phase 3 | 574 | Australasian Gastro-Intestinal Trials GroupNETWORK | 10 | Mar 4, 2025 | clinicaltrials |
| NCT02807636 | Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma(IMvigor130) | completed | Phase 3 | 1,213 | Hoffmann-La RocheINDUSTRY | 35 | Feb 24, 2025 | clinicaltrials |
| NCT02576509 | An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma | completed | Phase 3 | 743 | Bristol-Myers SquibbINDUSTRY | 22 | Feb 17, 2025 | clinicaltrials |
| NCT02437318 | Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.(SOLAR-1) | completed | Phase 3 | 572 | Novartis PharmaceuticalsINDUSTRY | 31 | Feb 13, 2025 | clinicaltrials |
| NCT02891824 | ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab(ATALANTE) | completed | Phase 3 | 614 | ARCAGY/ GINECO GROUPOTHER | 7 | Feb 11, 2025 | clinicaltrials |
| NCT01828112 | LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib | completed | Phase 3 | 231 | Novartis PharmaceuticalsINDUSTRY | 20 | Feb 7, 2025 | clinicaltrials |
| NCT01715285 | A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC) | completed | Phase 3 | 1,209 | Janssen Research & Development, LLCINDUSTRY | 33 | Feb 4, 2025 | clinicaltrials |
| NCT01855750 | A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma | completed | Phase 3 | 838 | Janssen Research & Development, LLCINDUSTRY | 27 | Feb 4, 2025 | clinicaltrials |
| NCT03357952 | A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 / Phase 3 | 10 | Janssen Research & Development, LLCINDUSTRY | 3 | Feb 4, 2025 | clinicaltrials |
| NCT03796858 | A Study of Guselkumab in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Alpha (Anti-TNF Alpha) Therapy(COSMOS) | completed | Phase 3 | 285 | Janssen Pharmaceutica N.V., BelgiumINDUSTRY | 14 | Feb 3, 2025 | clinicaltrials |
| NCT02576574 | Avelumab in First-line NSCLC (JAVELIN Lung 100) | completed | Phase 3 | 1,214 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 42 | Jan 31, 2025 | clinicaltrials |
| NCT03366272 | Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients(NIVEAU) | completed | Phase 2 / Phase 3 | 348 | Universität des SaarlandesOTHER | 8 | Jan 28, 2025 | clinicaltrials |
| NCT05348577 | Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)(CAPItello280) | active not recruiting | Phase 3 | 1,035 | AstraZenecaINDUSTRY | 22 | Jan 27, 2025 | clinicaltrials |
| NCT00418886 | Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients(ZEAL) | completed | Phase 3 | 698 | Genzyme, a Sanofi CompanyINDUSTRY | 21 | Dec 31, 2024 | clinicaltrials |
| NCT03836261 | Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL(AMPLIFY) | active not recruiting | Phase 3 | 984 | Acerta Pharma BVINDUSTRY | 27 | Dec 27, 2024 | clinicaltrials |
| NCT05477589 | Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML(SCRIPT-AML) | recruiting | Phase 3 | 170 | Vastra Gotaland RegionOTHER_GOV | 10 | Dec 19, 2024 | clinicaltrials |
| NCT02085408 | Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 3 | 727 | ECOG-ACRIN Cancer Research GroupNETWORK | 3 | Dec 13, 2024 | clinicaltrials |
| NCT02612311 | Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia(UNITY-CLL) | terminated | Phase 3 | 603 | TG Therapeutics, Inc.INDUSTRY | 7 | Dec 13, 2024 | clinicaltrials |
| NCT02626455 | Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)(CHRONOS-4) | terminated | Phase 3 | 551 | BayerINDUSTRY | 35 | Dec 11, 2024 | clinicaltrials |
| NCT03553836 | Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716) | active not recruiting | Phase 3 | 976 | Merck Sharp & Dohme LLCINDUSTRY | 16 | Nov 29, 2024 | clinicaltrials |
| NCT02181413 | A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant | completed | Phase 3 | 656 | TakedaINDUSTRY | 33 | Nov 19, 2024 | clinicaltrials |
| NCT03447769 | Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A(Canopy-A) | terminated | Phase 3 | 1,382 | Novartis PharmaceuticalsINDUSTRY | 41 | Oct 9, 2024 | clinicaltrials |
| NCT02028507 | Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors(PEARL) | completed | Phase 3 | 693 | Spanish Breast Cancer Research GroupOTHER | 4 | Sep 25, 2024 | clinicaltrials |
| NCT01285557 | Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial(DIGEST) | terminated | Phase 3 | 361 | Taiho Oncology, Inc.INDUSTRY | 20 | Sep 19, 2024 | clinicaltrials |
| NCT01724346 | Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 3 | 269 | Pharmacyclics LLC.INDUSTRY | 16 | Sep 19, 2024 | clinicaltrials |
| NCT02500043 | Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer | completed | Phase 3 | 507 | Taiho Oncology, Inc.INDUSTRY | 18 | Sep 3, 2024 | clinicaltrials |
| NCT04385368 | Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)(MERMAID-1) | completed | Phase 3 | 89 | AstraZenecaINDUSTRY | 33 | Aug 30, 2024 | clinicaltrials |
| NCT03110562 | Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma(BOSTON) | completed | Phase 3 | 402 | Karyopharm Therapeutics IncINDUSTRY | 21 | Aug 21, 2024 | clinicaltrials |
| NCT03402841 | Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients(OPINION) | completed | Phase 3 | 279 | AstraZenecaINDUSTRY | 19 | Aug 21, 2024 | clinicaltrials |
| NCT03498716 | A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer(IMpassion030) | terminated | Phase 3 | 2,199 | Hoffmann-La RocheINDUSTRY | 31 | Aug 21, 2024 | clinicaltrials |
| NCT04296890 | A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression(SORAYA) | completed | Phase 3 | 106 | ImmunoGen, Inc.INDUSTRY | 11 | Aug 7, 2024 | clinicaltrials |
| NCT02668653 | Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)(QuANTUM-First) | completed | Phase 3 | 539 | Daiichi SankyoINDUSTRY | 28 | Aug 6, 2024 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials